Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.81 |
| ▸ | GABRB2 | P47870 | 20/20 | 0.81 |
| ▸ | GABRD | O14764 | 19/20 | 0.81 |
| ▸ | GABRA4 | P48169 | 19/20 | 0.81 |
| ▸ | GABRP | O00591 | 18/20 | 0.81 |
| ▸ | GABRB1 | P18505 | 18/20 | 0.81 |
| ▸ | GABRG2 | P18507 | 18/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 18/20 | 0.81 |
| ▸ | GABRA5 | P31644 | 18/20 | 0.81 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.81 |
| ▸ | GABRA2 | P47869 | 18/20 | 0.81 |
| ▸ | GABRE | P78334 | 18/20 | 0.81 |
| ▸ | GABRA6 | Q16445 | 18/20 | 0.81 |
| ▸ | GABRG1 | Q8N1C3 | 18/20 | 0.81 |
| ▸ | GABRG3 | Q99928 | 18/20 | 0.81 |
| ▸ | GABRQ | Q9UN88 | 18/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22516226 | 1.00 | GABRA1 (0.81) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL17792263 | 1.00 | GABRA1 (0.81) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL26060827 | 0.92 | GABRA1 (0.69) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL23346583 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL21091386 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL14871146 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL23344276 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL23468933 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL19650972 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL3124023 | 0.89 | GABRP (1.00) | GABRA1GABRB2GABRDGABRA4GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898646-B1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3719030-B1 | 19-NOR NEUROACTIVE STEROIDS FOR INDUCING SEDATION | SAGE THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3481845-B1 | C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20220372067-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11396525-B2 | C17, C20, and C21 substituted neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11344563-B2 | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-9725481-B2 | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9365611-B2 | 19-NOR neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365611-B2 | 19-NOR neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2016082789-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160083418-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083417-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-C-BOUND HETEROARYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083418-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2014169832-A9 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014169831-A1 | 19-NOR C3,3-DISUBSTITUTED C21-C-BOUND HETEROARYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014169832-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372067-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | HSD17B7, HSD3B1, HSD17B3 | GABRA1 334/4885GABRB2 253/4885GABRD 700/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | GABRA1 13/4885GABRB2 8/4885GABRD 127/4885 |
| US-11396525-B2 | C17, C20, and C21 substituted neuroactive steroids and their methods of use | CNR1, CNR2, GABRA1 | GABRA1 3/4885GABRB2 24/4885GABRD 34/4885 |
| US-20160083417-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-C-BOUND HETEROARYL STEROIDS AND METHODS OF USE THEREOF | CYP11B1, HSD3B1, NR3C2 | GABRA1 62/4885GABRB2 83/4885GABRD 295/4885 |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | GABRA1 13/4885GABRB2 8/4885GABRD 127/4885 |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | GABRA1 13/4885GABRB2 8/4885GABRD 127/4885 |
| US-20160083418-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | GABRA1 42/4885GABRB2 53/4885GABRD 83/4885 |
| US-11344563-B2 | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof | CYP11B1, NR3C2, HSD3B1 | GABRA1 61/4885GABRB2 80/4885GABRD 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.